CV Sciences’ PlusCBD Oil™ Used in First Study Examining Clinical Benefit of CBD for Patients with PTSD
CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announced that its industry-dominating...
Edited Transcript of CVSI earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 CV Sciences Inc Earnings Call
CV Sciences, Inc. Reports First Quarter 2019 Financial Results
Record quarterly revenue Increased retail distribution by over 1,000 stores LAS VEGAS, May 08, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) ("CV Sciences" or the “Company”).
CV Sciences, Inc. to Present at Upcoming Investor Conferences
LAS VEGAS, May 07, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) a preeminent supplier and manufacturer of hemp CBD products.
CV Sciences, Inc. (CVSI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
There is No Slowdown Ahead for CBD Growth in 2019
Not only has it transformed multi-billion-dollar industries including alcohol, health and wellness, cigarettes, and the retail industry, it's impacting food, too. Better, the U.S. FDA could provide a...
CV Sciences, Inc. to Announce First Quarter 2019 Results on May 8, 2019
CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) announced that it will release financial results for its first quarter 2019 ended March 31, 2019, after the stock market closes...
With Strong Demand, More Top Retailers are Just Beginning to Sell CBD Products
Neiman Marcus is pushing ahead with CBD sales at some of its stores and online. Simon Property Group is partnering with Green Growth Brands to open 108 stores in its malls just in 2019. CVS will carry...
CV Sciences, Inc. Appoints Deloitte & Touche LLP as Auditor
LAS VEGAS, April 15, 2019 -- CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp CBD products,.
Three Companies Giving Investor the Biggest Exposure to CBD Growth
HOUSTON, TX / ACCESSWIRE / April 12, 2019 / According to the Brightfield Group, worldwide CBD sales are expected to soar from $591 million in 2018 to as high as $22 billion by 2022 - a compound growth...
CV Sciences, Inc., a life sciences organization, is focused on promoting healthy living through their pharmaceutical drug development efforts and portfolio of finished product brands. CV Sciences’ Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences’ Consumer Products Division delivers botanical‐based cannabidiol products